Latest News

Happy with previous assignments delivered by Aagami, its Netherlands HQ'd client has given Aagami a broader and long term assignment, for partnering in Asia region.

The client has a game changing First-in-class phase-3-ready drug candidate for Post-Operative Fibrosis (POF) with incredible adhesion prevention results.

The asset has an untapped $2.5 billion market potential. The drug prevents adhesion formation & delivers clinically relevant outcomes, key to surgeon adoption, reimbursement & commands premium pricing. Client recently released clinical trial results show that it is the first drug to show a statistically significant PREVENTION of adhesions following surgery.

Aagami is excited with this new assignment and is looking forward to enabling partnerships for the client in Asia.

Aagami team are happy to anounced that their Louisiana based Biotechnology client have given another assignment (3rd from them)  to support their cross border partnering. This time the mandate is for global and not restricted to any geography. In previous assignment, Aagami got a US$ 10 Million deal for the same client.

The client company specializes in innovative cancer treatment and their mission is to improve the overall patient condition through innovative bioimmunotherapy with proven treatment protocols, to lower deaths associated with cancer and reduce the cost of cancer treatment.

With a dedicated team in India, Aagami looks forward to put its best foot forward in bringing yet another success to its client who has known and appreciated Aagami work for a long time now.

This time, Aagami has a new client from South Korea. The recent trips to the country has been fruitful. Apart from this new assignment, more are in discussion. 

The assignment received is for outlicensing client's Anti-Retinal-Disease and Anti-cancer Drugs. 

Client has a novel and leading-edge HTS anti-HIV drug screening technique and Novel CPP technique and molecules. The mandate received is for North America region.

Updates at Aagami for May 2017:

  • New Client Win: Outreach and Business Development for a high growth US Med Tech company which has a promise to impact billions
  • New Client Win - Partnering support to a US based bio-targeted nanomedicines company with world-wide exclusive rights to a novel and innovative drug-targeting platform technology
  • Aagami to attend BIO International Convention, 40+ meetings already scheduled with pre-defined agenda.

Another day, Another assignment for Aaagami. Client is a high growth US MedTech, advancing the next generation of affordable, portable, minimally invasive surgical tools and technologies, which can be used everywhere, everyday, by everyone. Thus, has the promise to impact billions.

Aagami is excited to be a part of this inspiring and humanitarian opportunity. Aagami has deployed its specialised resources and connections, to draw water from the wells, for the client.